Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.96 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KRAS | P01116 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31298007 | 1.00 | PKM (0.96) | PKMDDAH1GAAPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27041735 | 0.98 | PKM (1.00) | PKMDDAH1GAAPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5205174 | 0.98 | PKM (1.00) | PKMDDAH1GAAPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5973175 | 0.98 | PKM (1.00) | PKMDDAH1GAAPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30689215 | 0.98 | PKM (1.00) | PKMDDAH1GAAPOLBSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6950609 | 0.85 | PKM (0.71) | PKMDDAH1GAAPOLBSMN1; SMN2 | |
| SCHEMBL7272840 | 0.85 | PKM (0.71) | PKMDDAH1GAAPOLBSMN1; SMN2 | |
| SCHEMBL31734838 | 0.85 | PKM (0.71) | PKMDDAH1GAAPOLBSMN1; SMN2 | |
| SCHEMBL711507 | 0.85 | PKM (0.71) | PKMDDAH1GAAPOLBSMN1; SMN2 | |
| SCHEMBL21941037 | 0.83 | PKM (0.69) | PKMDDAH1GAAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| EP-1506277-A1 | ENZYMATIC DETERGENT COMPOSITIONS | UNILEVER N.V. (NL) | 2005-02-16 | — | — | EP | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| WO-2003097780-A1 | ENZYMATIC DETERGENT COMPOSITIONS | UNILEVER N.V. (NL) | 2003-11-27 | — | — | WO | claimed |
| EP-1341893-A1 | ENZYMATIC DETERGENT COMPOSITIONS | UNILEVER N.V. (NL) | 2003-09-10 | — | — | EP | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| WO-2002048307-A1 | ENZYMATIC DETERGENT COMPOSITIONS | UNILEVER N.V. (NL) | 2002-06-20 | — | — | WO | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-10960088-B2 | Macrocycles, cobalt and iron complexes of same, and methods of making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-03-30 | — | — | US | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| EP-3016951-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
| US-5354866-A | Treating HIV infections | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0486948-A2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1992-05-27 | — | — | EP | disclosed |
| US-5104892-A | N-heteroalkyl substitutes 1-aryloxy-2-propanolamine | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-14 | — | — | US | disclosed |
| US-5084463-A | Cardiovascular disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-01-28 | — | — | US | disclosed |
| WO-1991009023-A1 | N-HETEROARALKYL-SUBSTITUTED 1-ARYLOXY-2-PROPANOLAMINE AND PROPYLAMINE DERIVATIVES POSSESSING CLASS III ANTIARRHYTHMIC ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | PKM 599/4885DDAH1 481/4885GAA 637/4885 |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | PKM 3862/4885DDAH1 1209/4885GAA 671/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | PKM 3742/4885DDAH1 674/4885GAA 3522/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | PKM 3862/4885DDAH1 1209/4885GAA 671/4885 |
| US-10960088-B2 | Macrocycles, cobalt and iron complexes of same, and methods of making and using same | ABCB7, FECH, CYC1 | PKM 1698/4885DDAH1 2659/4885GAA 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.